TFFP - Rasio utang marang kapitalisasi buku TFF Pharmaceuticals Inc.

Logo grafis TFF Pharmaceuticals Inc. (TFFP)

TFF Pharmaceuticals (TFFP) is currently executing a hard pivot, cutting costs and seeking to license its thin-film drying technology. Analyzing the chart on GURU.Markets, we see that the company's total debt-to-equity ratio currently stands at 0.02. The company is also developing inhalation powders through biolabs and creating dry vaccine formulations in collaboration with external drug developers.

TFFP (TFF Pharmaceuticals, Inc) riwayat Utang marang nilai buku saka 04.07.2022 nganti 21.12.2024
Barang utama TFF Pharma

A defensive portfolio requires strict monitoring of the issuer's financial stability. This indicator compares total liabilities to the book value of equity to determine the business's degree of dependence on borrowed funds. For TFF Pharmaceuticals (TFFP), this balance is critical when implementing automated thin-film freezing lines. A high debt load could limit the scaling of robotic production. The trend in the total debt-to-book capitalization ratio reflects the company's current margin of safety.

Pesaing TFF Pharmaceuticals

Utang-utang marang kapitalisasi buku HLN (Haleon plc)|kenvue.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Verona Pharma (VRNA)|MENS: Rasio utang marang aset resik|LGND (Ligand Pharma) - Rasio utang marang kapitalisasi buku|Amneal Corp (AMRX) - Utang marang nilai buku|PRGO (Perrigo Company plc) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku alvotech.com (ALVO)|Liquidia (LQDA) - Utang marang nilai buku|Rasio utang marang aset resik GLPG (Galapagos N.V.)|ANIP: Rasio utang marang kapitalisasi buku|MNKD - Utang-utang marang nilai buku|Utang marang nilai buku Amphastar Pharmaceuticals AMPH|PCRX - Utang marang modal buku|Utang-utang marang kapitalisasi buku ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku AQST (Aquestive Pharma)|Utang-utang marang nilai buku SCPH|Tectonic Therapeutic, Inc. (TECX) - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik tonixpharma.com TNXP|Utang marang nilai buku China SXT Pharmaceuticals, Inc. (SXTC)|Utang marang modal buku Eupraxia Pharmaceuticals, Inc. EPRX|Utang-utang marang kapitalisasi buku BioHarvest|EXOZ - Rasio utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku oramed.com (ORMP)|Rasio utang-utang marang kapitalisasi buku Entera Bio|HYFT - Utang marang nilai buku|Rasio utang marang aset resik ABVC|CPIX - Rasio utang marang kapitalisasi buku|Rasio utang-utang marang kapitalisasi buku Quantum BioPharma Corp (QNTM)|Utang-utang marang kapitalisasi buku FibroGen, Inc.|Rasio utang marang aset resik telomirpharma.com TELO|Rani Therapeutics Inc - Utang-utang marang kapitalisasi buku|SNYR: Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku rallybio.com RLYB|LEXX (Lexaria Bioscience Corp.) - Rasio utang marang aset resik|Rasio utang marang kapitalisasi buku PULM|Utang marang nilai buku Pheton|Utang-utang marang kapitalisasi buku APM|Utang-utang marang kapitalisasi buku Lyra Therapeutics Inc. (LYRA)|Impact BioMedical Inc - Utang-utang marang kapitalisasi buku|Utang marang nilai buku TNF Pharmaceuticals Inc. TNFA|YCBD (cbdMD Corp) - Utang-utang marang kapitalisasi buku|painreform.com (PRFX) - Utang-utang marang nilai buku|CYTO: Utang marang nilai buku|Utang-utang marang kapitalisasi buku Lipella Pharmaceuticals Inc|Optinose (OPTN) - Utang marang nilai buku|Utang marang modal buku Pieris Pharma|PROC (Procaps Group S.A.) - Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik petrospharma.com (PTPI)|Qilian International Holding - Utang-utang marang kapitalisasi buku|Utang marang nilai buku Acelyrin Inc. SLRN